4bz6 › Citations

Structural basis for the inhibition of histone deacetylase 8 (HDAC8), a key epigenetic player in the blood fluke Schistosoma mansoni.

<div class='caption-title'>smHDAC8 is a functional acetyl-L-lysine deacetylase that is essential for parasite infectivity.</div>
<div class='caption-title'>smHDAC8 adopts a canonical HDAC fold with specific external loops.</div>
<div class='caption-title'>Flipping-out of smHDAC8 phenylalanine 151 (F151) cannot be accommodated by major human HDACs.</div>
Marek M, Kannan S, Hauser AT, Moraes Mourão M, Caby S, Cura V, Stolfa DA, Schmidtkunz K, Lancelot J, Andrade L, Renaud JP, Oliveira G, Sippl W, Jung M, Cavarelli J, Pierce RJ, Romier C
OpenAccess logo PLoS Pathog 9 e1003645 (2013)
Related entries: 4bz5, 4bz7, 4bz8, 4bz9

Cited: 77 times
EuropePMC logo PMID: 24086136

Abstract

The treatment of schistosomiasis, a disease caused by blood flukes parasites of the Schistosoma genus, depends on the intensive use of a single drug, praziquantel, which increases the likelihood of the development of drug-resistant parasite strains and renders the search for new drugs a strategic priority. Currently, inhibitors of human epigenetic enzymes are actively investigated as novel anti-cancer drugs and have the potential to be used as new anti-parasitic agents. Here, we report that Schistosoma mansoni histone deacetylase 8 (smHDAC8), the most expressed class I HDAC isotype in this organism, is a functional acetyl-L-lysine deacetylase that plays an important role in parasite infectivity. The crystal structure of smHDAC8 shows that this enzyme adopts a canonical α/β HDAC fold, with specific solvent exposed loops corresponding to insertions in the schistosome HDAC8 sequence. Importantly, structures of smHDAC8 in complex with generic HDAC inhibitors revealed specific structural changes in the smHDAC8 active site that cannot be accommodated by human HDACs. Using a structure-based approach, we identified several small-molecule inhibitors that build on these specificities. These molecules exhibit an inhibitory effect on smHDAC8 but show reduced affinity for human HDACs. Crucially, we show that a newly identified smHDAC8 inhibitor has the capacity to induce apoptosis and mortality in schistosomes. Taken together, our biological and structural findings define the framework for the rational design of small-molecule inhibitors specifically interfering with schistosome epigenetic mechanisms, and further support an anti-parasitic epigenome targeting strategy to treat neglected diseases caused by eukaryotic pathogens.

Reviews - 4bz6 mentioned but not cited (1)

  1. Mercaptoacetamide: A promising zinc-binding group for the discovery of selective histone deacetylase 6 inhibitors. Tavares MT, Kozikowski AP, Shen S. Eur J Med Chem 209 112887 (2021)

Articles - 4bz6 mentioned but not cited (2)

  1. Structural basis for the inhibition of histone deacetylase 8 (HDAC8), a key epigenetic player in the blood fluke Schistosoma mansoni. Marek M, Kannan S, Hauser AT, Moraes Mourão M, Caby S, Cura V, Stolfa DA, Schmidtkunz K, Lancelot J, Andrade L, Renaud JP, Oliveira G, Sippl W, Jung M, Cavarelli J, Pierce RJ, Romier C. PLoS Pathog 9 e1003645 (2013)
  2. Repurposing of neprilysin inhibitor 'sacubitrilat' as an anti-cancer drug by modulating epigenetic and apoptotic regulators. Kumbhar N, Nimal S, Patil D, Kaiser VF, Haupt J, Gacche RN. Sci Rep 13 9952 (2023)


Reviews citing this publication (20)

  1. Histone deacetylase inhibitors in clinical studies as templates for new anticancer agents. Mottamal M, Zheng S, Huang TL, Wang G. Molecules 20 3898-3941 (2015)
  2. Inside HDACs with more selective HDAC inhibitors. Roche J, Bertrand P. Eur J Med Chem 121 451-483 (2016)
  3. HDAC8: a multifaceted target for therapeutic interventions. Chakrabarti A, Oehme I, Witt O, Oliveira G, Sippl W, Romier C, Pierce RJ, Jung M. Trends Pharmacol Sci 36 481-492 (2015)
  4. Targeting Class I Histone Deacetylases in a "Complex" Environment. Millard CJ, Watson PJ, Fairall L, Schwabe JWR. Trends Pharmacol Sci 38 363-377 (2017)
  5. Immunoepigenetics Combination Therapies: An Overview of the Role of HDACs in Cancer Immunotherapy. Banik D, Moufarrij S, Villagra A. Int J Mol Sci 20 E2241 (2019)
  6. The Search for Potent, Small-Molecule HDACIs in Cancer Treatment: A Decade After Vorinostat. Zagni C, Floresta G, Monciino G, Rescifina A. Med Res Rev 37 1373-1428 (2017)
  7. A Genetically Encoded, Phage-Displayed Cyclic-Peptide Library. Wang XS, Chen PC, Hampton JT, Tharp JM, Reed CA, Das SK, Wang DS, Hayatshahi HS, Shen Y, Liu J, Liu WR. Angew Chem Int Ed Engl 58 15904-15909 (2019)
  8. Targeting histone deacetylase 8 as a therapeutic approach to cancer and neurodegenerative diseases. Chakrabarti A, Melesina J, Kolbinger FR, Oehme I, Senger J, Witt O, Sippl W, Jung M. Future Med Chem 8 1609-1634 (2016)
  9. Enzyme Tunnels and Gates As Relevant Targets in Drug Design. Marques SM, Daniel L, Buryska T, Prokop Z, Brezovsky J, Damborsky J. Med Res Rev 37 1095-1139 (2017)
  10. Epigenetic control of gene function in schistosomes: a source of therapeutic targets? Cabezas-Cruz A, Lancelot J, Caby S, Oliveira G, Pierce RJ. Front Genet 5 317 (2014)
  11. Drugging the schistosome zinc-dependent HDACs: current progress and future perspectives. Marek M, Oliveira G, Pierce RJ, Jung M, Sippl W, Romier C. Future Med Chem 7 783-800 (2015)
  12. Chemotherapy for Fighting Schistosomiasis: Past, Present and Future. Mäder P, Rennar GA, Ventura AMP, Grevelding CG, Schlitzer M. ChemMedChem 13 2374-2389 (2018)
  13. Pathological Role of HDAC8: Cancer and Beyond. Kim JY, Cho H, Yoo J, Kim GW, Jeon YH, Lee SW, Kwon SH. Cells 11 3161 (2022)
  14. Histone Deacetylase (HDAC) Inhibitors for the Treatment of Schistosomiasis. Ghazy E, Abdelsalam M, Robaa D, Pierce RJ, Sippl W. Pharmaceuticals (Basel) 15 80 (2022)
  15. Schistosome sirtuins as drug targets. Lancelot J, Cabezas-Cruz A, Caby S, Marek M, Schultz J, Romier C, Sippl W, Jung M, Pierce RJ. Future Med Chem 7 765-782 (2015)
  16. Structure-activity relationships of hydroxamate-based histone deacetylase-8 inhibitors: reality behind anticancer drug discovery. Amin SA, Adhikari N, Jha T. Future Med Chem 9 2211-2237 (2017)
  17. Chemotherapy for human schistosomiasis: how far have we come? What's new? Where do we go from here? Dziwornu GA, Attram HD, Gachuhi S, Chibale K. RSC Med Chem 11 455-490 (2020)
  18. Modern approaches to accelerate discovery of new antischistosomal drugs. Neves BJ, Muratov E, Machado RB, Andrade CH, Cravo PV. Expert Opin Drug Discov 11 557-567 (2016)
  19. Epigenetics in Schistosomes: What We Know and What We Need Know. Liu W. Front Cell Infect Microbiol 6 149 (2016)
  20. The nonepigenetic role for small molecule histone deacetylase inhibitors in the regulation of cardiac function. Romanick SS, Ferguson BS. Future Med Chem 11 1345-1356 (2019)

Articles citing this publication (54)

  1. Effect of clinically approved HDAC inhibitors on Plasmodium, Leishmania and Schistosoma parasite growth. Chua MJ, Arnold MS, Xu W, Lancelot J, Lamotte S, Späth GF, Prina E, Pierce RJ, Fairlie DP, Skinner-Adams TS, Andrews KT. Int J Parasitol Drugs Drug Resist 7 42-50 (2017)
  2. Regulation of Schistosoma mansoni development and reproduction by the mitogen-activated protein kinase signaling pathway. Andrade LF, Mourão Mde M, Geraldo JA, Coelho FS, Silva LL, Neves RH, Volpini A, Machado-Silva JR, Araujo N, Nacif-Pimenta R, Caffrey CR, Oliveira G. PLoS Negl Trop Dis 8 e2949 (2014)
  3. HDAC8 and STAT3 repress BMF gene activity in colon cancer cells. Kang Y, Nian H, Rajendran P, Kim E, Dashwood WM, Pinto JT, Boardman LA, Thibodeau SN, Limburg PJ, Löhr CV, Bisson WH, Williams DE, Ho E, Dashwood RH. Cell Death Dis 5 e1476 (2014)
  4. Molecular basis for the antiparasitic activity of a mercaptoacetamide derivative that inhibits histone deacetylase 8 (HDAC8) from the human pathogen schistosoma mansoni. Stolfa DA, Marek M, Lancelot J, Hauser AT, Walter A, Leproult E, Melesina J, Rumpf T, Wurtz JM, Cavarelli J, Sippl W, Pierce RJ, Romier C, Jung M. J Mol Biol 426 3442-3453 (2014)
  5. The Epigenome of Schistosoma mansoni Provides Insight about How Cercariae Poise Transcription until Infection. Roquis D, Lepesant JM, Picard MA, Freitag M, Parrinello H, Groth M, Emans R, Cosseau C, Grunau C. PLoS Negl Trop Dis 9 e0003853 (2015)
  6. Epigenetic changes modulate schistosome egg formation and are a novel target for reducing transmission of schistosomiasis. Carneiro VC, de Abreu da Silva IC, Torres EJ, Caby S, Lancelot J, Vanderstraete M, Furdas SD, Jung M, Pierce RJ, Fantappié MR. PLoS Pathog 10 e1004116 (2014)
  7. Targeting Lysine Deacetylases (KDACs) in Parasites. Wang Q, Rosa BA, Nare B, Powell K, Valente S, Rotili D, Mai A, Marshall GR, Mitreva M. PLoS Negl Trop Dis 9 e0004026 (2015)
  8. Structure of 'linkerless' hydroxamic acid inhibitor-HDAC8 complex confirms the formation of an isoform-specific subpocket. Tabackman AA, Frankson R, Marsan ES, Perry K, Cole KE. J Struct Biol 195 373-378 (2016)
  9. HDAC8 substrate selectivity is determined by long- and short-range interactions leading to enhanced reactivity for full-length histone substrates compared with peptides. Castañeda CA, Wolfson NA, Leng KR, Kuo YM, Andrews AJ, Fierke CA. J Biol Chem 292 21568-21577 (2017)
  10. Tissue Degeneration following Loss of Schistosoma mansoni cbp1 Is Associated with Increased Stem Cell Proliferation and Parasite Death In Vivo. Collins JN, Collins JJ. PLoS Pathog 12 e1005963 (2016)
  11. A Novel Class of Schistosoma mansoni Histone Deacetylase 8 (HDAC8) Inhibitors Identified by Structure-Based Virtual Screening and In Vitro Testing. Simoben CV, Robaa D, Chakrabarti A, Schmidtkunz K, Marek M, Lancelot J, Kannan S, Melesina J, Shaik TB, Pierce RJ, Romier C, Jung M, Sippl W. Molecules 23 E566 (2018)
  12. HDAC8 functions in spindle assembly during mouse oocyte meiosis. Zhang K, Lu Y, Jiang C, Liu W, Shu J, Chen X, Shi Y, Wang E, Wang L, Hu Q, Dai Y, Xiong B. Oncotarget 8 20092-20102 (2017)
  13. Synthesis and Biological Investigation of Phenothiazine-Based Benzhydroxamic Acids as Selective Histone Deacetylase 6 Inhibitors. Vögerl K, Ong N, Senger J, Herp D, Schmidtkunz K, Marek M, Müller M, Bartel K, Shaik TB, Porter NJ, Robaa D, Christianson DW, Romier C, Sippl W, Jung M, Bracher F. J Med Chem 62 1138-1166 (2019)
  14. Elucidating the molecular bases of epigenetic inheritance in non-model invertebrates: the case of the root-knot nematode Meloidogyne incognita. Perfus-Barbeoch L, Castagnone-Sereno P, Reichelt M, Fneich S, Roquis D, Pratx L, Cosseau C, Grunau C, Abad P. Front Physiol 5 211 (2014)
  15. Target-based molecular modeling strategies for schistosomiasis drug discovery. Ferreira LG, Oliva G, Andricopulo AD. Future Med Chem 7 753-764 (2015)
  16. The repositioning of epigenetic probes/inhibitors identifies new anti-schistosomal lead compounds and chemotherapeutic targets. Whatley KCL, Padalino G, Whiteland H, Geyer KK, Hulme BJ, Chalmers IW, Forde-Thomas J, Ferla S, Brancale A, Hoffmann KF. PLoS Negl Trop Dis 13 e0007693 (2019)
  17. Repurposing pharma assets: an accelerated mechanism for strengthening the schistosomiasis drug development pipeline. Ramamoorthi R, Graef KM, Dent J. Future Med Chem 7 727-735 (2015)
  18. Evolutionary relationships among protein lysine deacetylases of parasites causing neglected diseases. Scholte LLS, Mourão MM, Pais FS, Melesina J, Robaa D, Volpini AC, Sippl W, Pierce RJ, Oliveira G, Nahum LA. Infect Genet Evol 53 175-188 (2017)
  19. Histone deacetylase inhibition modulates histone acetylation at gene promoter regions and affects genome-wide gene transcription in Schistosoma mansoni. Anderson L, Gomes MR, daSilva LF, Pereira ADSA, Mourão MM, Romier C, Pierce R, Verjovski-Almeida S. PLoS Negl Trop Dis 11 e0005539 (2017)
  20. Photochromic histone deacetylase inhibitors based on dithienylethenes and fulgimides. Wutz D, Gluhacevic D, Chakrabarti A, Schmidtkunz K, Robaa D, Erdmann F, Romier C, Sippl W, Jung M, König B. Org Biomol Chem 15 4882-4896 (2017)
  21. Methyl-CpG-binding (SmMBD2/3) and chromobox (SmCBX) proteins are required for neoblast proliferation and oviposition in the parasitic blood fluke Schistosoma mansoni. Geyer KK, Munshi SE, Whiteland HL, Fernandez-Fuentes N, Phillips DW, Hoffmann KF. PLoS Pathog 14 e1007107 (2018)
  22. The antischistosomal potential of GSK-J4, an H3K27 demethylase inhibitor: insights from molecular modeling, transcriptomics and in vitro assays. Lobo-Silva J, Cabral FJ, Amaral MS, Miyasato PA, de Freitas RP, Pereira ASA, Khouri MI, Barbosa MMF, Ramos PIP, Leite LCC, Asojo OA, Nakano E, Verjovski-Almeida S, Farias LP. Parasit Vectors 13 140 (2020)
  23. Histone deacetylase enzymes as potential drug targets of Neglected Tropical Diseases caused by cestodes. Vaca HR, Celentano AM, Macchiaroli N, Kamenetzky L, Camicia F, Rosenzvit MC. Int J Parasitol Drugs Drug Resist 9 120-132 (2019)
  24. In vitro activity of aryl-thiazole derivatives against Schistosoma mansoni schistosomula and adult worms. Pereira ASA, Silveira GO, Amaral MS, Almeida SMV, Oliveira JF, Lima MCA, Verjovski-Almeida S. PLoS One 14 e0225425 (2019)
  25. Long non-coding RNA levels can be modulated by 5-azacytidine in Schistosoma mansoni. Amaral MS, Maciel LF, Silveira GO, Olberg GGO, Leite JVP, Imamura LK, Pereira ASA, Miyasato PA, Nakano E, Verjovski-Almeida S. Sci Rep 10 21565 (2020)
  26. Synthesis, Crystallization Studies, and in vitro Characterization of Cinnamic Acid Derivatives as SmHDAC8 Inhibitors for the Treatment of Schistosomiasis. Bayer T, Chakrabarti A, Lancelot J, Shaik TB, Hausmann K, Melesina J, Schmidtkunz K, Marek M, Erdmann F, Schmidt M, Robaa D, Romier C, Pierce RJ, Jung M, Sippl W. ChemMedChem 13 1517-1529 (2018)
  27. Gene Expression Differences in Host Response to Schistosoma haematobium Infection. Dupnik KM, Reust MJ, Vick KM, Yao B, Miyaye D, Lyimo E, Mukerebe C, Mngara J, Kalluvya SE, de Dood CJ, Corstjens PLAM, van Dam GJ, Zhang T, Xiang J, Lee MH, Downs JA. Infect Immun 87 e00291-18 (2019)
  28. Congress First Barcelona Conference on Epigenetics and Cancer. Palau A, Perucho M, Esteller M, Buschbeck M. Epigenetics 9 468-475 (2014)
  29. Identification of novel multi-stage histone deacetylase (HDAC) inhibitors that impair Schistosoma mansoni viability and egg production. Guidi A, Saccoccia F, Gennari N, Gimmelli R, Nizi E, Lalli C, Paonessa G, Papoff G, Bresciani A, Ruberti G. Parasit Vectors 11 668 (2018)
  30. Inhibition mechanism of SAHA in HDAC: a revisit. Zhou J, Wu R, Luo HB. Phys Chem Chem Phys 17 29483-29488 (2015)
  31. Pharmacological inhibition of lysine-specific demethylase 1 (LSD1) induces global transcriptional deregulation and ultrastructural alterations that impair viability in Schistosoma mansoni. Coutinho Carneiro V, de Abreu da Silva IC, Amaral MS, Pereira ASA, Silveira GO, Pires DDS, Verjovski-Almeida S, Dekker FJ, Rotili D, Mai A, Lopes-Torres EJ, Robaa D, Sippl W, Pierce RJ, Borrello MT, Ganesan A, Lancelot J, Thiengo S, Fernandez MA, Vicentino ARR, Mourão MM, Coelho FS, Fantappié MR. PLoS Negl Trop Dis 14 e0008332 (2020)
  32. Structural insights of SmKDAC8 inhibitors: Targeting Schistosoma epigenetics through a combined structure-based 3D QSAR, in vitro and synthesis strategy. Ballante F, Reddy DR, Zhou NJ, Marshall GR. Bioorg Med Chem 25 2105-2132 (2017)
  33. Valproic acid as a potential inhibitor of Plasmodium falciparum histone deacetylase 1 (PfHDAC1): an in silico approach. Elbadawi MA, Awadalla MK, Hamid MM, Mohamed MA, Awad TA. Int J Mol Sci 16 3915-3931 (2015)
  34. Analysis of the interactome of Schistosoma mansoni histone deacetylase 8. Caby S, Pagliazzo L, Lancelot J, Saliou JM, Bertheaume N, Pierce RJ, Roger E. PLoS Negl Trop Dis 11 e0006089 (2017)
  35. First Fluorescent Acetylspermidine Deacetylation Assay for HDAC10 Identifies Selective Inhibitors with Cellular Target Engagement. Herp D, Ridinger J, Robaa D, Shinsky SA, Schmidtkunz K, Yesiloglu TZ, Bayer T, Steimbach RR, Herbst-Gervasoni CJ, Merz A, Romier C, Sehr P, Gunkel N, Miller AK, Christianson DW, Oehme I, Sippl W, Jung M. Chembiochem 23 e202200180 (2022)
  36. Editorial How has the genomics era impacted schistosomiasis drug discovery? Oliveira G, Pierce RJ. Future Med Chem 7 685-687 (2015)
  37. Hydroxamic acid-modified peptide microarrays for profiling isozyme-selective interactions and inhibition of histone deacetylases. Moreno-Yruela C, Bæk M, Vrsanova AE, Schulte C, Maric HM, Olsen CA. Nat Commun 12 62 (2021)
  38. Identification of histone deacetylase 10 (HDAC10) inhibitors that modulate autophagy in transformed cells. Zeyen P, Zeyn Y, Herp D, Mahmoudi F, Yesiloglu TZ, Erdmann F, Schmidt M, Robaa D, Romier C, Ridinger J, Herbst-Gervasoni CJ, Christianson DW, Oehme I, Jung M, Krämer OH, Sippl W. Eur J Med Chem 234 114272 (2022)
  39. Isophthalic Acid-Based HDAC Inhibitors as Potent Inhibitors of HDAC8 from Schistosoma mansoni. Stenzel K, Chakrabarti A, Melesina J, Hansen FK, Lancelot J, Herkenhöhner S, Lungerich B, Marek M, Romier C, Pierce RJ, Sippl W, Jung M, Kurz T. Arch Pharm (Weinheim) 350 (2017)
  40. An in silico mechanistic insight into HDAC8 activation facilitates the discovery of new small-molecule activators. Du J, Li W, Liu B, Zhang Y, Yu J, Hou X, Fang H. Bioorg Med Chem 28 115607 (2020)
  41. Aromatic side-chain flips orchestrate the conformational sampling of functional loops in human histone deacetylase 8. Shukla VK, Siemons L, Gervasio FL, Hansen DF. Chem Sci 12 9318-9327 (2021)
  42. Design, Synthesis and Biological Characterization of Histone Deacetylase 8 (HDAC8) Proteolysis Targeting Chimeras (PROTACs) with Anti-Neuroblastoma Activity. Darwish S, Ghazy E, Heimburg T, Herp D, Zeyen P, Salem-Altintas R, Ridinger J, Robaa D, Schmidtkunz K, Erdmann F, Schmidt M, Romier C, Jung M, Oehme I, Sippl W. Int J Mol Sci 23 7535 (2022)
  43. Effect of bee venom or proplis on molecular and parasitological aspects of Schistosoma mansoni infected mice. Mohamed AH, Hassab El-Nabi SE, Bayomi AE, Abdelaal AA. J Parasit Dis 40 390-400 (2016)
  44. The potential for histone deacetylase (HDAC) inhibitors as cestocidal drugs. Vaca HR, Celentano AM, Toscanini MA, Heimburg T, Ghazy E, Zeyen P, Hauser AT, Oliveira G, Elissondo MC, Jung M, Sippl W, Camicia F, Rosenzvit MC. PLoS Negl Trop Dis 15 e0009226 (2021)
  45. Binding Free Energy (BFE) Calculations and Quantitative Structure-Activity Relationship (QSAR) Analysis of Schistosoma mansoni Histone Deacetylase 8 (smHDAC8) Inhibitors. Simoben CV, Ghazy E, Zeyen P, Darwish S, Schmidt M, Romier C, Robaa D, Sippl W. Molecules 26 2584 (2021)
  46. Carbamates as Potential Prodrugs and a New Warhead for HDAC Inhibition. King K, Hauser AT, Melesina J, Sippl W, Jung M. Molecules 23 E321 (2018)
  47. Computer-Assisted Discovery of Alkaloids with Schistosomicidal Activity. Menezes RPB, Viana JO, Muratov E, Scotti L, Scotti MT. Curr Issues Mol Biol 44 383-408 (2022)
  48. Crystal structures of Schistosoma mansoni histone deacetylase 8 reveal a novel binding site for allosteric inhibitors. Saccoccia F, Pozzetti L, Gimmelli R, Butini S, Guidi A, Papoff G, Giannaccari M, Brogi S, Scognamiglio V, Gemma S, Ruberti G, Campiani G. J Biol Chem 298 102375 (2022)
  49. Development of First-in-Class Dual Sirt2/HDAC6 Inhibitors as Molecular Tools for Dual Inhibition of Tubulin Deacetylation. Sinatra L, Vogelmann A, Friedrich F, Tararina MA, Neuwirt E, Colcerasa A, König P, Toy L, Yesiloglu TZ, Hilscher S, Gaitzsch L, Papenkordt N, Zhai S, Zhang L, Romier C, Einsle O, Sippl W, Schutkowski M, Gross O, Bendas G, Christianson DW, Hansen FK, Jung M, Schiedel M. J Med Chem 66 14787-14814 (2023)
  50. Histone deacetylase 8 interacts with the GTPase SmRho1 in Schistosoma mansoni. Pagliazzo L, Caby S, Lancelot J, Salomé-Desnoulez S, Saliou JM, Heimburg T, Chassat T, Cailliau K, Sippl W, Vicogne J, Pierce RJ. PLoS Negl Trop Dis 15 e0009503 (2021)
  51. Schistosoma mansoni coactivator associated arginine methyltransferase 1 (SmCARM1) effect on parasite reproduction. Coelho FS, Gava SG, Andrade LF, Geraldo JA, Tavares NC, Lunkes FMN, Neves RH, Machado-Silva JR, Pierce RJ, Oliveira G, Mourão MM. Front Microbiol 14 1079855 (2023)
  52. Combattre les maladies négligées en ciblant sélectivement leurs enzymes épigénétiques : le cas de la désacétylase 8 (HDAC8) de Schistosoma mansoni. Marek M, Shaik TB, Jung M, Sippl W, Pierce RJ, Romier C. Biol Aujourdhui 210 311-320 (2016)
  53. Computational Insights into Natural Antischistosomal Metabolites as SmHDAC8 Inhibitors: Molecular Docking, ADMET Profiling, and Molecular Dynamics Simulation. Alzain AA, Mukhtar RM, Abdelmoniem N, Elbadwi FA, Hussien A, Garelnabi EAE, Osman W, Sherif AE, Khedr AIM, Ghazawi KF, Samman WA, Ibrahim SRM, Mohamed GA, Ashour A. Metabolites 13 658 (2023)
  54. Structure-Activity Relationship of Propargylamine-Based HDAC Inhibitors. Wünsch M, Senger J, Schultheisz P, Schwarzbich S, Schmidtkunz K, Michalek C, Klaß M, Goskowitz S, Borchert P, Praetorius L, Sippl W, Jung M, Sewald N. ChemMedChem 12 2044-2053 (2017)


Quick links